[go: up one dir, main page]

TW200515917A - Methods and compositions for the generation of a protective immune response against SARS-COV - Google Patents

Methods and compositions for the generation of a protective immune response against SARS-COV

Info

Publication number
TW200515917A
TW200515917A TW093127725A TW93127725A TW200515917A TW 200515917 A TW200515917 A TW 200515917A TW 093127725 A TW093127725 A TW 093127725A TW 93127725 A TW93127725 A TW 93127725A TW 200515917 A TW200515917 A TW 200515917A
Authority
TW
Taiwan
Prior art keywords
cov
compositions
generation
immune response
protective immune
Prior art date
Application number
TW093127725A
Other languages
Chinese (zh)
Inventor
Gary J Nabel
Wing-Pui Kong
Yue Huang
Zhi-Yong Yang
Original Assignee
Us Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Government filed Critical Us Government
Publication of TW200515917A publication Critical patent/TW200515917A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K16/102—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to novel methods and compositions for the generation of a protective immune response in humans and other animals against the coronavirus responsible for Severe Acute Respiratory Syndrome (SARS-CoV).
TW093127725A 2003-09-15 2004-09-14 Methods and compositions for the generation of a protective immune response against SARS-COV TW200515917A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50350803P 2003-09-15 2003-09-15
US55031704P 2004-03-08 2004-03-08

Publications (1)

Publication Number Publication Date
TW200515917A true TW200515917A (en) 2005-05-16

Family

ID=34381075

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093127725A TW200515917A (en) 2003-09-15 2004-09-14 Methods and compositions for the generation of a protective immune response against SARS-COV

Country Status (2)

Country Link
TW (1) TW200515917A (en)
WO (1) WO2005027963A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113521269A (en) * 2020-04-22 2021-10-22 生物技术Rna制药有限公司 Coronavirus vaccine
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1820020B (en) * 2003-05-06 2010-04-28 技术持有有限公司 SARS-coronavirus virus-like particle and application method
WO2005012337A2 (en) * 2003-07-15 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
CN1914226B (en) 2003-11-25 2012-02-01 达纳-法伯癌症研究院有限公司 Antibodies against SARS-COV and methods of use thereof
WO2006071250A2 (en) * 2004-04-05 2006-07-06 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Soluble fragments of the sars-cov spike glycoprotein
PL3981437T3 (en) 2014-04-23 2025-02-24 Modernatx, Inc. Nucleic acid vaccines
KR20160145813A (en) * 2014-04-25 2016-12-20 다나-파버 캔서 인스티튜트 인크. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
EP4349404A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
US20230143215A1 (en) * 2020-04-23 2023-05-11 Isa Pharmaceuticals B.V. Immunization against sars-cov-related diseases
CN111505286A (en) * 2020-04-28 2020-08-07 郑州伊美诺生物技术有限公司 Novel coronavirus specific antibody double-antigen sandwich E L ISA detection kit and preparation method thereof
WO2021231659A1 (en) * 2020-05-12 2021-11-18 Sapphire Biotech, Inc. Neutralizing antibody testing and treatment
US11129890B1 (en) * 2020-05-19 2021-09-28 Vigene Biosciences, Inc. Non-integrating HIV-1 comprising mutant RT/IN proteins and the SARS-CoV-2 spike protein
CN112999333A (en) * 2021-02-04 2021-06-22 安域生物制药(杭州)有限公司 Application of multi-target blocking peptide in preventing and treating new coronavirus infection
CN113444745A (en) * 2021-05-25 2021-09-28 安徽省立医院(中国科学技术大学附属第一医院) Construction of virus S protein mutant pseudovirus disc and vaccine evaluation application thereof
WO2025019352A2 (en) * 2023-07-14 2025-01-23 Modernatx, Inc. Mers-cov mrna vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2828405B1 (en) * 2001-08-09 2005-06-24 Virbac Sa ANTI-CORONAVIRUS VACCINE
AU2004230485B2 (en) * 2003-04-10 2009-01-22 Novartis Vaccines And Diagnostics, Inc. The severe acute respiratory syndrome coronavirus
CN1449826A (en) * 2003-05-27 2003-10-22 武汉大学 Gene vaccine for anti SARS coronal virus and use thereof
CN1449831A (en) * 2003-06-03 2003-10-22 中国人民解放军第二军医大学 DNA vaccine pVPS2 for SARS virus
CN1185011C (en) * 2003-06-03 2005-01-19 中国人民解放军第二军医大学 DNA vaccine pVPS for SARS virus
CA2532196A1 (en) * 2003-06-18 2005-01-20 Chinese National Human Genome Center At Shanghai Characterization of the earliest stages of the severe acute respiratory syndrome (sars) virus and uses thereof
CA2533113A1 (en) * 2003-07-21 2005-02-03 Government Of The United States Of America As Represented By The Secreta Ry Of The Department Of Health And Human Services National Institutes Of Soluble fragments of the sars-cov spike glycoprotein

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113521269A (en) * 2020-04-22 2021-10-22 生物技术Rna制药有限公司 Coronavirus vaccine
US11779659B2 (en) 2020-04-22 2023-10-10 BioNTech SE RNA constructs and uses thereof
US11925694B2 (en) 2020-04-22 2024-03-12 BioNTech SE Coronavirus vaccine
US12133899B2 (en) 2020-04-22 2024-11-05 BioNTech SE Coronavirus vaccine
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12208136B2 (en) 2021-11-29 2025-01-28 BioNTech SE Coronavirus vaccine
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine

Also Published As

Publication number Publication date
WO2005027963A2 (en) 2005-03-31
WO2005027963A3 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
TW200515917A (en) Methods and compositions for the generation of a protective immune response against SARS-COV
MX2007003078A (en) Imidazoquinoline compounds.
AU2002360488A8 (en) Methods and devices for detection and therapy of atheromatous plaque
TWI369981B (en) Hmb compositions and uses thereof
ZA200506094B (en) Compositions, methods and systems for inferring bovine traits
AU2003255845A8 (en) Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
AU2008243079A1 (en) Compositions and methods for generating an immune response
DE50202328D1 (en) AMIDOFUNCTIONAL AMINOPOLYDIORGANOSILOXANE
DK1377280T3 (en) Fillers as sense of satiety
PT1185649E (en) PROMOTER OF THE GENE OF MIOSTATINA AND INITIATION OF ITS ACTIVATION
IL162895A0 (en) Benzamides and compositions benzamides for use as fungicide
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
NO20073026L (en) 2-Alkoxy-3,4,5-trihydroxyalkylamides, preparation and compositions thereof, and use thereof
ECSP045493A (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLIBANSERINE POLYMORPH A
MY143677A (en) Amide prodrug of gemcitabine, compositions and use thereof
WO2004069173A3 (en) Methods for modulating an inflammatory response
UA97346C2 (en) Stable emulsion composition
WO2007022321A3 (en) Substituted indoles and use thereof
MY139425A (en) Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol
MXPA05008131A (en) Methods for modulating an inflammatory response.
MY137953A (en) New association of an anti-atherothrombotic agent and an anti-platelet-aggregation agent
TW200706173A (en) Oral composition comprising carbamylating agent
ITMI20021366A1 (en) NUTRACEUTICAL COMPOSITIONS AND FOOD SUPPLEMENTS CONTAINING NADH
PL348550A1 (en) Ibdv mutant, vaccine containing it for protecting poultry against a disease caused by ibdv and method of protecting poultry against such disease
TW200643000A (en) Reaction product of resorcin and methyl ethyl ketone